• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

骨髓衰竭:病理生理学与管理

Bone marrow failure: pathophysiology and management.

作者信息

Jacobs P

机构信息

Department of Haematology, Wynberg Hospital, Cape Town, South Africa.

出版信息

Dis Mon. 1995 Apr;41(4):201-89.

PMID:7698059
Abstract

Morphologically, bone marrow is made up of a relatively mature but heterogenous population, fueled by a tiny pool of microscopically unrecognizable stem and progenitor cells. This complex tissue has the responsibility of maintaining our hematopoietic and, to a large extent, immunologic integrity, both of which are indispensable for health and, indeed, survival. Perhaps not surprisingly, bone marrow is the target of genetic, autoimmune, and environmental insults. Although robust, it has only a limited number of responses, one of which is reduction in cellular output, sometimes with superimposed qualitative abnormalities, and this is defined as bone marrow failure. Bone marrow failure is a diverse entity but can be logically explained and classified on a pathophysiologic basis. Thus the major recognizable categories of bone marrow failure are congenital and acquired defects. Each of these is subdivided according to the number of cell lines involved, over and above which the severity of the damage will determine reversibility. In each case, the natural history dictates management, and this ranges from short-term growth factor support to biologic immune response modulation and finally to bone marrow transplantation. In the past, many clinicopathologic variants of bone marrow failure were described, although their etiology was obscure and effective therapy was unavailable. This changed dramatically, however, when experimental hematologists, using radiobiology models, uncovered the dynamic nature of blood formation. Cardinal observations included the way in which spontaneous recovery followed irradiation, the central role played by pluripotential stem cells, and the integral participation of stroma in modulating this entire process. Understanding was refined once bone marrow cultures became available while, in parallel, the use of in-bred mouse strains launched the era of allogeneic transplantation. These approaches were combined, and the broad principles that govern basal or constitutive production emerged. Stem cells, with their characteristic commitment to self-renewal, exist at the apex of a hierarchy and generate a tier of proliferating progenitors that, in turn, give rise to a large postmitotic compartment of precursors that mature into distinctive myeloid and lymphoid lineages. The reserve potential is enormous, and output can be induced to meet even greatly increased demands. These events reflect the interaction of growth factors with a balancing set of negative regulators. The link between such diverse functions resides, to a large extent, in accessory cells and matrix geographically organized in what is now described as the hematopoietic inductive microenvironment. Many details of these meticulously orchestrated processes are obscure.(ABSTRACT TRUNCATED AT 400 WORDS)

摘要

从形态学上讲,骨髓由相对成熟但异质性的细胞群体组成,由一小群显微镜下难以识别的干细胞和祖细胞维持其功能。这种复杂的组织负责维持我们的造血功能,并且在很大程度上维持免疫完整性,这两者对于健康乃至生存都是不可或缺的。或许不足为奇的是,骨髓是遗传、自身免疫和环境损伤的靶点。尽管骨髓功能强大,但其应对机制有限,其中之一是细胞输出减少,有时还伴有质量异常,这被定义为骨髓衰竭。骨髓衰竭是一个多样化的病症,但可以从病理生理学角度进行合理的解释和分类。因此,骨髓衰竭主要可识别的类别是先天性和后天性缺陷。每一类又根据受累细胞系的数量进一步细分,除此之外,损伤的严重程度将决定其可逆性。在每种情况下,自然病程决定治疗方法,范围从短期生长因子支持到生物免疫反应调节,最终到骨髓移植。过去,虽然描述了许多骨髓衰竭的临床病理变异型,但其病因不明且缺乏有效的治疗方法。然而,当实验血液学家利用放射生物学模型揭示了血液生成的动态本质时,情况发生了巨大变化。主要观察结果包括照射后自发恢复的方式、多能干细胞所起的核心作用以及基质在调节整个过程中的不可或缺的参与。一旦有了骨髓培养技术,理解就更加深入,与此同时,近交系小鼠品系的使用开启了同种异体移植的时代。这些方法相结合,产生了关于基础或组成性造血的广泛原则。干细胞具有自我更新的独特能力,处于层级结构的顶端,产生一层增殖祖细胞,这些祖细胞进而产生大量不再分裂的前体细胞区室,这些前体细胞成熟为独特的髓系和淋巴系细胞。其储备潜力巨大,甚至可以诱导增加输出以满足大幅增加的需求。这些事件反映了生长因子与一组平衡的负调节因子之间的相互作用。这些多样功能之间的联系在很大程度上存在于辅助细胞和基质中,它们在现在被称为造血诱导微环境的区域中按地理方式组织起来。这些精心编排的过程的许多细节仍不清楚。(摘要截选至400字)

相似文献

1
Bone marrow failure: pathophysiology and management.骨髓衰竭:病理生理学与管理
Dis Mon. 1995 Apr;41(4):201-89.
2
Long-term bone marrow culture in persons with Fanconi anemia and bone marrow failure.
Blood. 1994 Jan 15;83(2):336-9.
3
Congenital failure of hematopoiesis in the newborn infant.新生儿先天性造血功能衰竭。
Clin Perinatol. 1984 Jun;11(2):417-31.
4
Physician Education: Myelodysplastic Syndrome.医师教育:骨髓增生异常综合征
Oncologist. 1996;1(4):284-287.
5
[Hereditary bone marrow failure syndromes].[遗传性骨髓衰竭综合征]
Rev Invest Clin. 1997 May;49 Suppl 1:22-7.
6
An abnormal bone marrow microenvironment contributes to hematopoietic dysfunction in Fanconi anemia.异常的骨髓微环境导致范可尼贫血中的造血功能障碍。
Haematologica. 2017 Jun;102(6):1017-1027. doi: 10.3324/haematol.2016.158717. Epub 2017 Mar 24.
7
Studies of W mutant mice provide evidence for alternate mechanisms capable of activating hematopoietic stem cells.对W突变小鼠的研究为能够激活造血干细胞的替代机制提供了证据。
Exp Hematol. 1996 Feb;24(2):185-94.
8
The mechanisms involved in the impairment of hematopoiesis after autologous bone marrow transplantation.自体骨髓移植后造血功能受损所涉及的机制。
Leuk Lymphoma. 1997 Jan;24(3-4):239-56. doi: 10.3109/10428199709039012.
9
[Progress in biology and therapy of aplastic anemia and other conditions of bone marrow failure].再生障碍性贫血及其他骨髓衰竭病症的生物学与治疗进展
Postepy Hig Med Dosw. 1992;46(1):21-51.
10
The membrane-bound isoform of stem cell factor synergizes with soluble flt3 ligand in supporting early hematopoietic cells in long-term cultures of normal and aplastic anemia bone marrow.干细胞因子的膜结合异构体与可溶性fms样酪氨酸激酶3配体协同作用,在正常和再生障碍性贫血骨髓的长期培养中支持早期造血细胞。
Exp Hematol. 1998 May;26(5):365-73.

引用本文的文献

1
Mesenchymal Stem Cell Benefits Observed in Bone Marrow Failure and Acquired Aplastic Anemia.间充质干细胞在骨髓衰竭和获得性再生障碍性贫血中的益处
Stem Cells Int. 2017;2017:8076529. doi: 10.1155/2017/8076529. Epub 2017 Dec 3.
2
Therapeutic effect of cyclosporine A in thrombocytopenia after myeloablative chemotherapy in acute myeloid leukaemia.
Med Oncol. 1997 Mar;14(1):43-6. doi: 10.1007/BF02990945.